Assessment of Cardiac Remodeling-A Chance for Novel Cardiac Biomarkers?

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Jul 9

PMID 32635167

Citations 1

Authors

Peter Jirak

Moritz Mirna

Bernhard Wernly

Vera Paar

Uta C Hoppe

Michael Lichtenauer

Affiliations

Soon will be listed here.

Abstract

Biomarkers are defined as "cellular, biochemical or molecular alterations that are measurable in biological media such as human tissues, cells, or fluids", providing "biological characteristics that can be objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention "according to Hulka et al [...].

Citing Articles

Soluble ST2 as a Biomarker for Predicting Right Ventricular Dysfunction in Acute Pulmonary Embolism.

Uyanik M, Cinar A, Gedikli O, Tuna T, Avci B J Clin Med. 2024; 13(23).

PMID: 39685669 PMC: 11642172. DOI: 10.3390/jcm13237211.

References

Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Simic D, Radovanovic S, Simic T . Novel Biomarkers of Heart Failure. Adv Clin Chem. 2017; 79:93-152. DOI: 10.1016/bs.acc.2016.09.002. View

Ovchinnikova E, Schmitter D, Vegter E, Ter Maaten J, Valente M, Liu L . Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail. 2015; 18(4):414-23. DOI: 10.1002/ejhf.332. View

Aimo A, Januzzi Jr J, Bayes-Genis A, Vergaro G, Sciarrone P, Passino C . Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week. J Am Coll Cardiol. 2019; 74(17):2193-2203. DOI: 10.1016/j.jacc.2019.08.1039. View

Kim S, Song M, Min H, Hwang I, Baek S, Kwon T . miRNA biogenesis-associated RNase III nucleases Drosha and Dicer are upregulated in colorectal adenocarcinoma. Oncol Lett. 2017; 14(4):4379-4383. PMC: 5605964. DOI: 10.3892/ol.2017.6674. View

Watson C, Gupta S, OConnell E, Thum S, Glezeva N, Fendrich J . MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail. 2015; 17(4):405-15. PMC: 4418397. DOI: 10.1002/ejhf.244. View

McCarthy C, Januzzi Jr J . Soluble ST2 in Heart Failure. Heart Fail Clin. 2017; 14(1):41-48. DOI: 10.1016/j.hfc.2017.08.005. View

Mohr A, Mott J . Overview of microRNA biology. Semin Liver Dis. 2015; 35(1):3-11. PMC: 4797991. DOI: 10.1055/s-0034-1397344. View

Mirna M, Rohm I, Jirak P, Wernly B, Baz L, Paar V . Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH). Heart Lung Circ. 2019; 29(3):337-344. DOI: 10.1016/j.hlc.2019.03.004. View

Jirak P, Mirna M, Wernly B, Paar V, Thieme M, Betge S . Analysis of novel cardiovascular biomarkers in patients with peripheral artery disease. Minerva Med. 2018; 109(6):443-450. DOI: 10.23736/S0026-4806.18.05628-8. View

10.

Lichtenauer M, Jirak P, Wernly B, Paar V, Rohm I, Jung C . A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure. Eur J Intern Med. 2017; 44:31-38. DOI: 10.1016/j.ejim.2017.05.027. View

11.

Pascual-Figal D, Lax A, Perez-Martinez M, Asensio-Lopez M, Sanchez-Mas J . Clinical relevance of sST2 in cardiac diseases. Clin Chem Lab Med. 2015; 54(1):29-35. DOI: 10.1515/cclm-2015-0074. View

12.

Jenkins W, Roger V, Jaffe A, Weston S, AbouEzzeddine O, Jiang R . Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective. Am J Med. 2017; 130(9):1112.e9-1112.e15. PMC: 5572469. DOI: 10.1016/j.amjmed.2017.02.034. View

13.

Zagidullin N, Motloch L, Gareeva D, Hamitova A, Lakman I, Krioni I . Combining Novel Biomarkers for Risk Stratification of Two-Year Cardiovascular Mortality in Patients with ST-Elevation Myocardial Infarction. J Clin Med. 2020; 9(2). PMC: 7073894. DOI: 10.3390/jcm9020550. View

14.

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M . MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; 456(7224):980-4. DOI: 10.1038/nature07511. View

15.

Talman V, Ruskoaho H . Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 2016; 365(3):563-81. PMC: 5010608. DOI: 10.1007/s00441-016-2431-9. View

16.

Azevedo P, Polegato B, Minicucci M, Paiva S, Zornoff L . Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment. Arq Bras Cardiol. 2015; 106(1):62-9. PMC: 4728597. DOI: 10.5935/abc.20160005. View

17.

Li L, Zhao Q, Kong W . Extracellular matrix remodeling and cardiac fibrosis. Matrix Biol. 2018; 68-69:490-506. DOI: 10.1016/j.matbio.2018.01.013. View

18.

Naylor S . Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn. 2003; 3(5):525-9. DOI: 10.1586/14737159.3.5.525. View

19.

Nakamura M, Sadoshima J . Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 2018; 15(7):387-407. DOI: 10.1038/s41569-018-0007-y. View

20.

Kakkar R, Lee R . The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008; 7(10):827-40. PMC: 4277436. DOI: 10.1038/nrd2660. View